📇 Rhumatologue · PARIS CEDEX 14 · (75) · Mixte

M SALIM ARACTINGI

Pourquoi vous devez consulter ce praticien

5 raisons identifiées

Plateau technique de référence
Assistance publique – Hôpitaux de Paris (APHP) — équipements et expertise pointus pour les cas complexes
Auteur de référence en rhumatologie
35 articles scientifiques publiés — un praticien à la pointe de la recherche
Encadrant universitaire
Forme la prochaine génération de rhumatologues (1 thèse dirigée)
Disponibilité géographique
2 lieux d'exercice — choisissez celui qui vous arrange
Délais de RDV courts dans la région
336.2 rhumatos / 100 000 hab. — département bien doté

Rhumatologue

📍 PARIS CEDEX 14 (75)MixteRPPS 10000442128

🎓 1 thèse dirigée

✨ Génération du profil synthétique IA en cours…

Direction de thèses

🎓 1 thèse dirigée

Etudes des mécanismes d'action de diverses modalités thérapeutiques dans des modèles de plaies chroniques
Doctorant·e : Peter Kanaan
Sciences de la vie et de la sante🎓 Université Paris Cité

Source theses.fr — signal de direction d'équipe / statut PU-PH (à confirmer via le site universitaire).

Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.

Top publications · les plus citées

Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial

Annals of the rheumatic diseases · 2019

📚 314 citations🎯 RCR 12.46Top 2% NIH🩺 Clinique🔓 Open Access📄 PDF gratuit ↗

Cardiovascular morbidity and mortality in psoriasis and psoriatic arthritis: a systematic literature review

Journal of the European Academy of Dermatology and Venereology : JEADV · 2013

📚 242 citations🎯 RCR 9.21Top 3% NIH🔓 Open Access📄 PDF gratuit ↗

Lire l'abstract Crossref ↓

AbstractPrevious epidemiological studies have demonstrated a high prevalence of cardiovascular (CV) risk factors in psoriasis patients, including metabolic syndrome, cigarette smoking, obesity, hypertension, diabetes mellitus, insulin resistance and dyslipidaemia. An increase in CV morbidity and mortality attributable to psoriasis is still under question.Primary objective: to assess CV morbidity and mortality in psoriasis and psoriatic arthritis (PsA) including stroke, coronary artery disease, myocardial infarction (MI) and peripheral artery disease. Secondary objectives: to assess if psoriasis per se is an independent CV risk factor and if psoriasis severity is a predictor of CV risk. We also evaluated the effect of conventional systemic treatments for psoriasis on CV mortality.A systematic literature search was carried out from 1980 to December 2011, in the Embase, Medline and Cochrane Library databases, in English and French using a combination of keywords including (Psoriasis) OR (Psoriatic arthritis) AND (Myocardial infarction) OR (Coronaropathy) OR (Stroke) OR (Cardiovascular) AND (Methotrexate) AND (Ciclosporin) AND (Retinoids).Of the 929 identified references, 33 observational studies evaluating the rates of cardiovascular events (CVE) in patients with psoriasis and PsA compared with controls were selected. Meta‐analysis of both cohort and cross‐sectional studies showed an increased risk of MI with Odds Ratio (OR) of 1.25 (95% CI 1.03–1.52) and 1.57 (95% CI 1.08–2.27) in psoriasis and PsA, respectively, compared with the general population. The risk of MI was more pronounced for patients having severe psoriasis and for patients with psoriasis of early onset. It remained significantly elevated after controlling for major CV risk factors. The meta‐analysis identified a small, but significant association between psoriasis, PsA and coronary artery disease with an OR between 1.19 (95% CI 1.14–1.24) for cross‐sectional studies, 1.20 (95% CI 1.13–1.27) for cohort studies and 1.84 (95% CI 1.09–3.09) for case–control studies. The risk of coronary artery disease seemed to be more pronounced in patients with severe psoriasis and in patients with psoriasis of early onset. The meta‐analysis assessing the risk of stroke gave inconclusive results: analysis of cross‐sectional studies suggested that psoriasis patients had a slightly higher risk of stroke with an OR of 1.14 (95% CI 1.08–1.99), whereas the meta‐analysis of cohort studies failed to show an association. There was also an increased risk of peripheral artery disease in psoriasis. No significant increased risk of CV mortality could be shown for both psoriasis and PsA patients. The use of methotrexate was associated with a reduced incidence of cardiovascular disease in two studies. The use of etretinate was associated with a reduction of CV mortality in one study. Potential selection bias such as the ‘healthy user effect’ prevents from drawing definite conclusions.There may be a small, but significant increased risk of CVE, but not of CV mortality in psoriasis and PsA patients. The psoriasis attributable risk remains difficult to assess due to confounding factors. The moderate quality of CV risk factors reporting in studies should be acknowledged. In addition, heterogeneity in study design, outcome definition and assessment represent major limitations. Nevertheless, screening and management of CV risk factors are important in psoriasis.

Prevalence of undiagnosed psoriatic arthritis among psoriasis patients: Systematic review and meta-analysis

Journal of the American Academy of Dermatology · 2015

📚 214 citations🎯 RCR 9.68Top 3% NIH

Cookies & analyse de trafic

M SALIM ARACTINGI

Pourquoi vous devez consulter ce praticien

Direction de thèses

Lieux de consultation(2)

Tarifs & secteur de conventionnement

Prendre rendez-vous & contact

Top publications · les plus citées

Publications scientifiques (35) — classées par pathologie

Transversal10

Revue générale7

Sclérodermie4

Épidémiologie & registres3

Revue / méta-analyse3

Essai clinique2

Lupus2

Sjögren2

Anti-TNF1

Biothérapies non-anti-TNF1

Case report / série1

csDMARDs1

Pharmacovigilance1

Recommandations1

Vascularites1

Partager cette fiche